Bacillus calmette-guerin substrain connaught live antigen Uses, Dosage, Side Effects and more
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
| Trade Name | Bacillus calmette-guerin substrain connaught live antigen |
| Generic | Bacillus calmette-guerin substrain connaught live antigen |
| Bacillus calmette-guerin substrain connaught live antigen Other Names | BCG, Live, Connaught Strain |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
Bacillus calmette-guerin substrain connaught live antigen is also used to associated treatment for these conditions: Carcinoma in situ of urinary bladder, Primary stage T1 papillary tumors, Primary stage Ta papillary tumors, Recurrent stage T1 papillary tumors, Recurrent stage Ta papillary tumors, Salvage therapy
